[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352758-105":59,"doc-detail-352758-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","car-t-cells-in-solid-tumors-engineering-biomarkers-translational-pathways-and-the-road-ahead","CAR-T cells in solid tumors - engineering, biomarkers, translational pathways and the road ahead","","Chimeric antigen receptor (CAR) T-cell therapy has reshaped treatment of hematologic malignancies through antigen-specific targeting and durable responses, yet its extension to solid tumors is constrained by biological barriers. Limited translation is driven by antigen heterogeneity, poor tumor infiltration, and strong immunosuppressive and metabolic pressures in the tumor microenvironment, which collectively promote dysfunction, exhaustion, and reduced persistence. This review synthesizes recent CAR-T advances and emphasizes systems-level engineering that couples tumor biology, spatial context, and cellular metabolism, including in vivo CAR programming, logic-gated/multi-antigen designs, and armored CAR-T strategies plus computational and spatial multi-omics guidance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-cells-in-solid-tumors-engineering-biomarkers-translational-pathways-and-the-road-ahead/352758/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-cells-in-solid-tumors-engineering-biomarkers-translational-pathways-and-the-road-ahead/352758.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What main barriers limit CAR-T translation from hematologic cancers to solid tumors?","Question",{"text":113,"@type":114},"Solid tumor translation is limited by antigen heterogeneity, inefficient tumor infiltration, and immunosuppressive plus metabolic constraints within the tumor microenvironment, which drive CAR-T dysfunction, exhaustion, and limited persistence.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What engineering strategies does the review highlight for solid tumors?",{"text":118,"@type":114},"The review highlights systems-level strategies such as in vivo CAR programming, logic-gated and multi-antigen receptor designs, and armored CAR-T cells engineered to resist immunosuppression and metabolic stress.",{"name":120,"@type":111,"acceptedAnswer":121},"How do computational modeling and artificial intelligence contribute according to the review?",{"text":122,"@type":114},"They increasingly guide antigen selection, CAR circuit design, and predictive assessment of therapeutic responses, complementing biological and spatial data.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352758,1790212333,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Review  \nPUBLISHED 01 April 2026  \nDOI 10.3389/fimmu.2026.1796675  \nOPEN ACCESS  \nEDITED BY  \nArchana Thakur,  \nUniversity of Virginia, United States  \nREVIEWED BY  \nWeian Zhu,  \nSun Yat-sen University, China Eknath D. Ahire,  \nMET Bhujbal Knowledge City, India  \n*CORRESPONDENCE  \nAhmed Yaqinuddin  \n [ayaqinuddin@alfaisal.edu](ayaqinuddin@alfaisal.edu)  \n†These authors have contributed equally to this work and share second authorship  \nRECEIVED 26 January 2026  \nREVISED 10 March 2026  \nACCEPTED 17 March 2026  \nPUBLISHED 01 April 2026  \nCITATION  \nAl Shaer NSH, Masoud I, Tleyjeh A, AlAttas AA, Al-Attas MA, Khan MI and Yaqinuddin A (2026) CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.  \nFront. Immunol. 17:1796675 .  \ndoi: 10.3389/fimmu.2026.1796675  \nCOPYRIGHT  \n© 2026 Al Shaer, Masoud, Tleyjeh, AlAttas, Al-Attas, Khan and Yaqinuddin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead  \nNada Saed Homod Al Shaer 1, Ibraheem Masoud 1†, Aya Tleyjeh 1†, Attas Alawi Al-Attas 1†, Maryam Alawi Al-Attas 1†,  \nMohammed Imran Khan 1,2 and Ahmed Yaqinuddin 1*  \n1College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, 2 King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia  \nChimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of hematologic malignancies by enabling antigen-speciﬁc tumor targeting and durable clinical responses. However, its translation to solid tumors has been limited by fundamental biological barriers, including antigen heterogeneity, poor tumor inﬁltration, and profound immunosuppressive and metabolic constraints within the tumor microenvironment. These factors collectively drive CAR-T cell dysfunction, exhaustion, and limited persistence, resulting in modest and inconsistent clinical efﬁcacy. This review provides a concept-driven synthesis of recent advances in CAR-T cell therapy for solid tumors, with a speciﬁc focus on systems-level engineering strategies that integrate tumor biology, spatial context, and cellular metabolism. We highlight emerging approaches such as in vivo CAR programming, logic-gated and multi-antigen receptor designs, and armored CAR-T cells engineered to resist immunosuppression and metabolic stress. Importantly, this review goes beyond descriptive engineering advances by emphasizing the growing role of computational modeling, artiﬁcial intelligence, and spatial multi-omics in guiding antigen selection, CAR circuit design, and predictive assessment of therapeutic responses. Unlike prior reviews that primarily summarize antigen targets or CAR engineering strategies, this review integrates biological barriers in solid tumors with emerging engineering solutions to provide a conceptual framework for the development and clinical translation of nextgeneration CAR-T therapies. By integrating biological determinants of failure with rational engineering solutions, the review delineates translational pathways that link mechanistic insight to clinical implementation. This review advances the ﬁeld by framing CAR-T therapy for solid tumors as a systems engineering challenge rather than a single-target optimization problem. By integrating immunology, bioengineering, computational sciences, and spatial biology, we outline aroadmap for the development of safer, more durable, and context-aware CART therapies. Continued progress will depend on tumor-speciﬁc antigen discovery, interdisciplinary collaboration, and scalable m","cbCain5L9f2fFLdR","https://ap.wps.com/l/cbCain5L9f2fFLdR","pdf",1843051,21,"English","# Introduction\n## Development and clinical milestones of CAR-T therapy\n# Translating CAR-T therapy to solid tumors\n## Key biological barriers in the solid tumor microenvironment\n# Systems-level engineering strategies\n## In vivo CAR programming and multi-antigen/logic-gated designs\n## Armored CAR-T cells for immunosuppression and metabolic stress resistance\n# Biomarkers, computation, and spatial multi-omics\n## Antigen selection, CAR circuit design, and predictive response assessment\n# Translational roadmap for next-generation CAR-T therapies","[{\"question\":\"What main barriers limit CAR-T translation from hematologic cancers to solid tumors?\",\"answer\":\"Solid tumor translation is limited by antigen heterogeneity, inefficient tumor infiltration, and immunosuppressive plus metabolic constraints within the tumor microenvironment, which drive CAR-T dysfunction, exhaustion, and limited persistence.\"},{\"question\":\"What engineering strategies does the review highlight for solid tumors?\",\"answer\":\"The review highlights systems-level strategies such as in vivo CAR programming, logic-gated and multi-antigen receptor designs, and armored CAR-T cells engineered to resist immunosuppression and metabolic stress.\"},{\"question\":\"How do computational modeling and artificial intelligence contribute according to the review?\",\"answer\":\"They increasingly guide antigen selection, CAR circuit design, and predictive assessment of therapeutic responses, complementing biological and spatial data.\"}]","CAR-T cells in solid tumors - engineering, biomarkers, translational pathways and the road ahead | PDF",1790101247,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9122eea3837701073483834fb03cc3c9.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24de8675ff15049886fc61a2b8444e8b.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/178ebc04b69fa7720b4fc816b046e75f.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a39f705ed0fb370846348c04ad8428e.webp",980,1385]